J Kahwaji
Overview
Explore the profile of J Kahwaji including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
203
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gaye N, Ndiaye-Diop M, Fall M, Ka M, Fall S, Diop A, et al.
Bull Soc Pathol Exot
. 2019 Dec;
112(3):137-146.
PMID: 31825191
Neuro-Behçet (NB) African studies are mainly North African, but Sub-Saharan Africa is not to be outdone. Our aim was to describe diagnostic and therapeutic features of NB in a Senegalese...
2.
Choi J, Aubert O, Vo A, Loupy A, Haas M, Puliyanda D, et al.
Am J Transplant
. 2017 Feb;
17(9):2381-2389.
PMID: 28199785
Extending the functional integrity of renal allografts is the primary goal of transplant medicine. The development of donor-specific antibodies (DSAs) posttransplantation leads to chronic active antibody-mediated rejection (cAMR) and transplant...
3.
Jordan S, Choi J, Kahwaji J, Vo A
Transplant Proc
. 2016 May;
48(3):806-8.
PMID: 27234741
Therapeutic interventions aimed at the human complement system are recognized as potentially important strategies for the treatment of inflammatory and autoimmune diseases because there is often evidence of complement-mediated injury...
4.
Jordan S, Choi J, Kahwaji J, Vo A
Transplant Proc
. 2016 May;
48(3):802-5.
PMID: 27234740
The presence of HLA antibodies remains a significant and often impenetrable barrier to kidney transplantation, leading to increased morbidity and mortality for patients remaining on long-term dialysis. In recent years,...
5.
Toyoda M, Thomas D, Ahn G, Kahwaji J, Mirocha J, Chu M, et al.
Transpl Infect Dis
. 2015 Oct;
17(6):838-47.
PMID: 26437369
Background: Desensitization (DES) with intravenous immunoglobulin (IVIG) + rituximab is effective, safe, and increases the transplantation rate in human leukocyte antigen-sensitized patients. However, reports of progressive multifocal leukoencephalopathy (PML) caused...
6.
Jordan S, Reinsmoen N, Lai C, Cao K, Kahwaji J, Peng A, et al.
Transplant Proc
. 2012 Feb;
44(1):60-1.
PMID: 22310579
For broadly human leukocyte antigen-sensitized patients (HS; calculated panel-reactive antibody >80%), options for deceased donor (DD) transplantation are extremely limited. Data from United Network for Organ Sharing (2000-2009) indicate that...
7.
Jordan S, Toyoda M, Kahwaji J, Vo A
Am J Transplant
. 2011 Jan;
11(2):196-202.
PMID: 21219579
Intravenous immunoglobulin products (IVIG) are derived from pooled human plasma from thousands of donors and have been used for the treatment of primary immunodeficiency disorders for nearly 30 years. IVIG...
8.
Hashmi S, Poommipanit N, Kahwaji J, Bunnapradist S
Minerva Med
. 2008 Feb;
98(6):713-29.
PMID: 18299684
Kidney transplantation is the treatment of choice for end stage renal disease patients. Recent advances, including newer immunosuppressants, revision of organ allocation policies, and better medical care of renal transplant...